Clinical implications of miRNAs in the pathogenesis, diagnosis and therapy of pancreatic cancer

Satyanarayana Rachagani, Muzafar A Macha, Nicholas Heimann, Parthasarathy Seshacharyulu, Dhanya Haridas, Seema Chugh, Surinder Kumar Batra

Research output: Contribution to journalReview article

53 Citations (Scopus)

Abstract

Despite considerable progress being made in understanding pancreatic cancer (PC) pathogenesis, it still remains the 10th most often diagnosed malignancy in the world and 4th leading cause of cancer related deaths in the United States with a five year survival rate of only 6%. The aggressive nature, lack of early diagnostic and prognostic markers, late clinical presentation, and limited efficacy of existing treatment regimens make PC a lethal cancer with high mortality and poor prognosis. Therefore, novel reliable biomarkers and molecular targets are urgently needed to combat this deadly disease. MicroRNAs (miRNAs) are short (19-24 nucleotides) non-coding RNA molecules implicated in the regulation of gene expression at post-transcriptional level and play significant roles in various physiological and pathological conditions. Aberrant expression of miRNAs has been reported in several cancers including PC and is implicated in PC pathogenesis and progression, suggesting their utility in diagnosis, prognosis and therapy. In this review, we summarize the role of several miRNAs that regulate various oncogenes (KRAS) and tumor suppressor genes (p53, p16, SMAD4, etc.) involved in PC development, their prospective roles as diagnostic and prognostic markers and as a therapeutic targets.

Original languageEnglish (US)
Pages (from-to)16-33
Number of pages18
JournalAdvanced Drug Delivery Reviews
Volume81
DOIs
StatePublished - Jan 1 2015

Fingerprint

MicroRNAs
Pancreatic Neoplasms
Neoplasms
Biomarkers
Therapeutics
Untranslated RNA
Gene Expression Regulation
Tumor Suppressor Genes
Oncogenes
Survival Rate
Nucleotides
Mortality

Keywords

  • Diagnosis
  • MiRNA
  • Pancreatic cancer
  • Pathogenesis
  • Therapy

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Clinical implications of miRNAs in the pathogenesis, diagnosis and therapy of pancreatic cancer. / Rachagani, Satyanarayana; Macha, Muzafar A; Heimann, Nicholas; Seshacharyulu, Parthasarathy; Haridas, Dhanya; Chugh, Seema; Batra, Surinder Kumar.

In: Advanced Drug Delivery Reviews, Vol. 81, 01.01.2015, p. 16-33.

Research output: Contribution to journalReview article

Rachagani, Satyanarayana ; Macha, Muzafar A ; Heimann, Nicholas ; Seshacharyulu, Parthasarathy ; Haridas, Dhanya ; Chugh, Seema ; Batra, Surinder Kumar. / Clinical implications of miRNAs in the pathogenesis, diagnosis and therapy of pancreatic cancer. In: Advanced Drug Delivery Reviews. 2015 ; Vol. 81. pp. 16-33.
@article{03ac1311c5354c79aec75206f58cf95a,
title = "Clinical implications of miRNAs in the pathogenesis, diagnosis and therapy of pancreatic cancer",
abstract = "Despite considerable progress being made in understanding pancreatic cancer (PC) pathogenesis, it still remains the 10th most often diagnosed malignancy in the world and 4th leading cause of cancer related deaths in the United States with a five year survival rate of only 6{\%}. The aggressive nature, lack of early diagnostic and prognostic markers, late clinical presentation, and limited efficacy of existing treatment regimens make PC a lethal cancer with high mortality and poor prognosis. Therefore, novel reliable biomarkers and molecular targets are urgently needed to combat this deadly disease. MicroRNAs (miRNAs) are short (19-24 nucleotides) non-coding RNA molecules implicated in the regulation of gene expression at post-transcriptional level and play significant roles in various physiological and pathological conditions. Aberrant expression of miRNAs has been reported in several cancers including PC and is implicated in PC pathogenesis and progression, suggesting their utility in diagnosis, prognosis and therapy. In this review, we summarize the role of several miRNAs that regulate various oncogenes (KRAS) and tumor suppressor genes (p53, p16, SMAD4, etc.) involved in PC development, their prospective roles as diagnostic and prognostic markers and as a therapeutic targets.",
keywords = "Diagnosis, MiRNA, Pancreatic cancer, Pathogenesis, Therapy",
author = "Satyanarayana Rachagani and Macha, {Muzafar A} and Nicholas Heimann and Parthasarathy Seshacharyulu and Dhanya Haridas and Seema Chugh and Batra, {Surinder Kumar}",
year = "2015",
month = "1",
day = "1",
doi = "10.1016/j.addr.2014.10.020",
language = "English (US)",
volume = "81",
pages = "16--33",
journal = "Advanced Drug Delivery Reviews",
issn = "0169-409X",
publisher = "Elsevier",

}

TY - JOUR

T1 - Clinical implications of miRNAs in the pathogenesis, diagnosis and therapy of pancreatic cancer

AU - Rachagani, Satyanarayana

AU - Macha, Muzafar A

AU - Heimann, Nicholas

AU - Seshacharyulu, Parthasarathy

AU - Haridas, Dhanya

AU - Chugh, Seema

AU - Batra, Surinder Kumar

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Despite considerable progress being made in understanding pancreatic cancer (PC) pathogenesis, it still remains the 10th most often diagnosed malignancy in the world and 4th leading cause of cancer related deaths in the United States with a five year survival rate of only 6%. The aggressive nature, lack of early diagnostic and prognostic markers, late clinical presentation, and limited efficacy of existing treatment regimens make PC a lethal cancer with high mortality and poor prognosis. Therefore, novel reliable biomarkers and molecular targets are urgently needed to combat this deadly disease. MicroRNAs (miRNAs) are short (19-24 nucleotides) non-coding RNA molecules implicated in the regulation of gene expression at post-transcriptional level and play significant roles in various physiological and pathological conditions. Aberrant expression of miRNAs has been reported in several cancers including PC and is implicated in PC pathogenesis and progression, suggesting their utility in diagnosis, prognosis and therapy. In this review, we summarize the role of several miRNAs that regulate various oncogenes (KRAS) and tumor suppressor genes (p53, p16, SMAD4, etc.) involved in PC development, their prospective roles as diagnostic and prognostic markers and as a therapeutic targets.

AB - Despite considerable progress being made in understanding pancreatic cancer (PC) pathogenesis, it still remains the 10th most often diagnosed malignancy in the world and 4th leading cause of cancer related deaths in the United States with a five year survival rate of only 6%. The aggressive nature, lack of early diagnostic and prognostic markers, late clinical presentation, and limited efficacy of existing treatment regimens make PC a lethal cancer with high mortality and poor prognosis. Therefore, novel reliable biomarkers and molecular targets are urgently needed to combat this deadly disease. MicroRNAs (miRNAs) are short (19-24 nucleotides) non-coding RNA molecules implicated in the regulation of gene expression at post-transcriptional level and play significant roles in various physiological and pathological conditions. Aberrant expression of miRNAs has been reported in several cancers including PC and is implicated in PC pathogenesis and progression, suggesting their utility in diagnosis, prognosis and therapy. In this review, we summarize the role of several miRNAs that regulate various oncogenes (KRAS) and tumor suppressor genes (p53, p16, SMAD4, etc.) involved in PC development, their prospective roles as diagnostic and prognostic markers and as a therapeutic targets.

KW - Diagnosis

KW - MiRNA

KW - Pancreatic cancer

KW - Pathogenesis

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=84922254330&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922254330&partnerID=8YFLogxK

U2 - 10.1016/j.addr.2014.10.020

DO - 10.1016/j.addr.2014.10.020

M3 - Review article

C2 - 25453266

AN - SCOPUS:84922254330

VL - 81

SP - 16

EP - 33

JO - Advanced Drug Delivery Reviews

JF - Advanced Drug Delivery Reviews

SN - 0169-409X

ER -